Conditions: Schizophrenia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 40
Healthy volunteers: no

Brief summary:
The primary objective of the current study is to investigate the safety and tolerability of BI 409306 in schizophrenic patients following oral administration of multiple low, medium, and high doses over 14 days.

A secondary objective is the exploration of the pharmacokinetics and pharmacodynamics of BI 409306 in schizophrenic patients.

Detailed description:

Arms:
arm 1: low dose, once daily arm 2: medium dose, once daily arm 3: high dose, once daily arm 4: placebo, once daily

Interventions: intervention 1: Placebo intervention 2: BI 409306
Intervention descriptions: intervention 1: matching placebo intervention 2: BI 409306

Protocol document: